

Principal Investigator Signature Page

**NON-INTERVENTIONAL  
FINAL STUDY REPORT**

**A Post-Marketing Surveillance of the Abuse of Eluxadoline using Poison Centre Data in  
the United States and Canada**

**Study Number:** CMO-EPI-GI-0582  
Final Report

Signatory Primary Investigator:



29 May 2020

---

Richard C. Dart, MD, PHD  
President, Canadian Consumer Product and  
Pharmaceutical Safety Inc.  
20 Holly Street, Suite 200, Toronto, Ontario,  
Canada M4S 3E8  
Director, Rocky Mountain Poison & Drug  
Safety 777 Bannock Street, MC 0180, Denver,  
Colorado, United States 80204

---

Date

## PASS information

<b>Title</b>	A Post-Marketing Surveillance of the Abuse of Eluxadoline using Poison Centre Data in the United States and Canada
<b>Version identifier of the final study report</b>	N/A
<b>Date of last version of the final study report</b>	N/A
<b>EU PAS register number</b>	EUPAS25247
<b>Active substance</b>	Eluxadoline ATC Code: A07DA06
<b>Medicinal product</b>	Viberzi 75 mg film-coated tablets Viberzi 100 mg film-coated tablets
<b>Product reference</b>	N/A
<b>Procedure number</b>	N/A
<b>Marketing authorisation holder(s)</b>	Allergan Inc. 85 Enterprise Blvd., Suite 500 Markham, Ontario Canada L6G 0B5 1-800-668-6424
<b>Joint PASS</b>	No
<b>Research question and objectives</b>	<p><u>Primary Objectives:</u></p> <p>a) To quantify the rate of abuse and serious adverse events for eluxadoline during a 3-year post approval period</p> <p><u>Secondary Objectives:</u></p> <p>a) To describe characteristics in terms of exposures and patient demographics of eluxadoline exposures reported to United States and Canadian poison centers</p> <p>b) To describe the medical outcomes associated with eluxadoline exposures reported to United States and Canadian poison centers</p>

<b>Title</b>	A Post-Marketing Surveillance of the Abuse of Eluxadoline using Poison Centre Data in the United States and Canada
<b>Country(-ies) of study</b>	Canada and United States
<b>Author</b>	Richard C. Dart, MD, PhD

## Marketing authorisation holder(s)

Marketing authorisation holder(s)	Allergan Inc. 85 Enterprise Blvd., Suite 500 Markham, Ontario Canada L6G 0B5 1-800-668-6424
MAH contact person	Ahunna Ukah, PhD Director, Epidemiology <a href="mailto:Ahunna.ukah@allergan.com">Ahunna.ukah@allergan.com</a> +1 916 953 9408 Rhiannon Konig Senior Manager, Regulatory Affairs <a href="mailto:Rhiannon.konig@allergan.com">Rhiannon.konig@allergan.com</a> 905 940 7353

## Approval Page, Allergan

<b>Project Title</b>	A Post-Marketing Surveillance of the Abuse of Eluxadoline using Poison Centre Data in the United States and Canada
<b>Protocol ID Number</b>	CMO-EPI-GI-0582
<b>Effective Date</b>	June 24, 2020
<b>Author</b>	Richard C. Dart, MD, PhD President, Canadian Consumer Product and Pharmaceutical Safety Inc. Director, Rocky Mountain Poison & Drug Safety
<b>Version</b>	1.0

The following people have reviewed the report and give their approval:

---

Darren Weissman, MD  
Assoc. VP, Medical Safety Physician  
Chief Medical Office

*Signature*

*Date*

---

Anita Bhagroo Verga, DrPH  
Executive Director, Epidemiology  
Research and Development

*Signature*

*Date*

---

Ilse Sjöholm, MScPharm  
Associate VP, EU QPPV  
Pharmacovigilance and Patient Safety

*Signature*

*Date*

## Table of contents

<b>PASS information .....</b>	<b>2</b>
<b>Marketing authorisation holder(s) .....</b>	<b>4</b>
<b>Approval Page, Allergan .....</b>	<b>5</b>
<b>1. Abstract.....</b>	<b>8</b>
<b>2. List of abbreviations .....</b>	<b>Error! Bookmark not defined.</b>
<b>3. Investigators .....</b>	<b>Error! Bookmark not defined.</b>
<b>4. Other responsible parties .....</b>	<b>Error! Bookmark not defined.</b>
<b>5. Milestones .....</b>	<b>Error! Bookmark not defined.</b>
<b>6. Rationale and background .....</b>	<b>Error! Bookmark not defined.</b>
<b>7. Research question and objectives .....</b>	<b>Error! Bookmark not defined.</b>
<b>8. Amendments and updates .....</b>	<b>Error! Bookmark not defined.</b>
<b>9. Research methods .....</b>	<b>Error! Bookmark not defined.</b>
9.1. Study design .....	<b>Error! Bookmark not defined.</b>
9.2. Setting.....	<b>Error! Bookmark not defined.</b>
9.3. Subjects.....	<b>Error! Bookmark not defined.</b>
9.4. Variables.....	<b>Error! Bookmark not defined.</b>
9.5. Data sources and measurement.....	<b>Error! Bookmark not defined.</b>
9.6. Bias .....	<b>Error! Bookmark not defined.</b>
9.7. Study size.....	<b>Error! Bookmark not defined.</b>
9.8. Data transformation .....	<b>Error! Bookmark not defined.</b>
9.9. Statistical methods.....	<b>Error! Bookmark not defined.</b>
9.9.1. Main summary measures .....	<b>Error! Bookmark not defined.</b>
9.9.2. Main statistical methods .....	<b>Error! Bookmark not defined.</b>
9.9.3. Missing values .....	<b>Error! Bookmark not defined.</b>
9.9.4. Sensitivity analyses.....	<b>Error! Bookmark not defined.</b>
9.9.5. Amendments to the statistical analysis plan .....	<b>Error! Bookmark not defined.</b>
9.10. Quality control.....	<b>Error! Bookmark not defined.</b>
<b>10. Results.....</b>	<b>Error! Bookmark not defined.</b>
10.1. Participants .....	<b>Error! Bookmark not defined.</b>
10.1.1. American Association of Poison Control Centers' National Poison Data System.....	<b>Error! Bookmark not defined.</b>
10.1.2. Canadian Poison Centre Network Program .....	<b>Error! Bookmark not defined.</b>
10.2. Descriptive data .....	<b>Error! Bookmark not defined.</b>
10.2.1. American Association of Poison Control Centers' National Poison Data System.....	<b>Error! Bookmark not defined.</b>
10.2.2. Canadian Poison Centre Network Program .....	<b>Error! Bookmark not defined.</b>
10.3. Outcome data.....	<b>Error! Bookmark not defined.</b>
10.3.1. American Association of Poison Control Centers' National Poison Data System.....	<b>Error! Bookmark not defined.</b>
10.3.2. Canadian Poison Centre Network Program .....	<b>Error! Bookmark not defined.</b>

10.4. Main results .....	<b>Error! Bookmark not defined.</b>
10.4.1. American Association of Poison Control Centers' National Poison Data System.....	<b>Error! Bookmark not defined.</b>
10.4.2. Canadian Poison Centre Network Program .....	<b>Error! Bookmark not defined.</b>
10.5. Other analyses.....	<b>Error! Bookmark not defined.</b>
10.5.1. American Association of Poison Control Centers' National Poison Data System.....	<b>Error! Bookmark not defined.</b>
10.5.2. Canadian Poison Centre Network Program .....	<b>Error! Bookmark not defined.</b>
10.6. Adverse events/adverse reactions .....	<b>Error! Bookmark not defined.</b>
<b>11. Discussion.....</b>	<b>Error! Bookmark not defined.</b>
11.1. Key results .....	<b>Error! Bookmark not defined.</b>
11.2. Limitations.....	<b>Error! Bookmark not defined.</b>
11.3. Interpretation .....	<b>Error! Bookmark not defined.</b>
11.4. Generalizability .....	<b>Error! Bookmark not defined.</b>
<b>12. Other information.....</b>	<b>Error! Bookmark not defined.</b>
<b>13. Conclusion .....</b>	<b>Error! Bookmark not defined.</b>
<b>14. References.....</b>	<b>Error! Bookmark not defined.</b>
<b>Appendices.....</b>	<b>Error! Bookmark not defined.</b>
<b>Annex 1. List of stand-alone documents .....</b>	<b>Error! Bookmark not defined.</b>
<b>Annex 2. Additional information.....</b>	<b>Error! Bookmark not defined.</b>

## 1. Abstract

### *Title*

A Post-Marketing Surveillance of the Abuse of Eluxadoline using Poison Centre Data in Canada and the United States

### *Keywords*

Poison center, exposure, eluxadoline, abuse, Viberzi

### *Marketing Authorisation Holder(s)*

AbbVie, Inc.

1400 Sheridan Rd

North Chicago, IL, United States

1-847-932-7900

### *Names and affiliations of principal investigators*

Richard C. Dart, MD, PhD

President, Canadian Consumer Product and Pharmaceutical Safety Inc.

Director, Rocky Mountain Poison & Drug Safety

### *Rationale and background*

Eluxadoline (Viberzi®), a mixed  $\mu$ -opioid receptor agonist,  $\delta$ -opioid receptor antagonist, and  $\kappa$ -opioid receptor agonist is approved for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. The use of opioid agonists is associated with potential for abuse or misuse. An overdose of eluxadoline may result in symptoms resulting from an exaggeration of the known pharmacodynamic effects of the medicinal product. Health Canada has requested that Allergan monitor the drug abuse/overdose potential of eluxadoline in the post-marketing setting. Using data from calls made to poison centers in the United States and Canada, this study describes a) the level of abuse and serious adverse events of eluxadoline since approval in the United States and Canada and b) the characteristics of exposures involving eluxadoline in the United States and Canada.

### *Primary Objectives*

a) To quantify the rate of abuse and serious adverse events for eluxadoline during a 3-year post approval period

### ***Secondary Objectives***

- a) To describe characteristics in terms of exposures and patient demographics of eluxadoline exposures reported to United States and Canadian poison centers
- b) To describe the medical outcomes associated with eluxadoline exposures reported to United States and Canadian poison centers

### ***Study design***

Retrospective observational surveillance study using data from the National Poison Data System in the United States and the Canadian Poison Centre Network Program in Canada.

### ***Setting***

Telephone calls received from the general public and healthcare professionals to poison centers for the reporting and management of poison related exposures or injuries.

### ***Subjects and study size, including dropouts***

All cases of human exposure to eluxadoline recorded in the National Poison Data System as originating in the United States during a 3-year period (January 2017 to December 2019) were identified and included in the analysis. All cases of human exposure to eluxadoline recorded in the Canadian Poison Centre Network Program during a 2-year period (January 2018 to December 2019) were identified and included in the analysis.

### ***Variables and data sources***

Secondary data collected by the National Poison Data System were used. They include:

- Patient demographics (age, gender)
- Number of substances involved in exposure
- Reason for exposure (intentional, unintentional, intentional abuse, intentional misuse, pediatric unintentional general)
- Route of exposure (ingestion, inhalation/nasal, parenteral, other, unknown) for single substance exposures (eluxadoline exposures only)
- Major medical outcome, hospitalization, or death (serious adverse event)
- Medical outcomes (no effect/minor effect/moderate effect/major effect/death/no follow-up)

### ***Results***

- In total there were 123 exposures involving eluxadoline reported to poison centers in the United States from 2017 through 2019.

- Of the 123 exposures involving eluxadoline reported to poison centers in the United States, no intentional abuse exposures were reported, and 14 exposures categorized as a serious adverse event were reported. One death was reported.
- The majority of exposures (N=86, 70%) were unintentional.
- There were 16 (13.0%) unintentional pediatric exposures.
- Almost all exposures were via the ingestion route of administration except 1 case with an unknown route of exposure.
- There were zero exposures involving eluxadoline reported in the Canadian Poison Centre Network in 2018 and 2019.

### ***Discussion***

There were no intentional abuse exposures mentioning eluxadoline in Canada or the United States. Fourteen exposures resulting in serious adverse events were reported and all were located in the United States. The majority of eluxadoline exposures were unintentional; 16 involved pediatric patients. There were no exposures involving eluxadoline regardless of motivation reported in Canada.